logo
logo

Tvardi Therapeutics Raises $74 Million In Series B Financing To Advance Clinical Programs

Jun 23, 2021•about 4 years ago

Amount Raised

$74 Million

Round Type

series b

Houston

Description

Tvardi Therapeutics, Inc. (“Tvardi”) a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, has closed a $74 million Series B financing. The financing was led by new investors Slate Path Capital, Palkon Capital, ArrowMark Partners, and 683 Capital, with continued support and participation by existing investors, including Sporos Bioventures. In conjunction with the financing, Jamie McNab, Partner at Slate Path Capital, will join the Tvardi Board of Directors.

Company Information

Company

Tvardi Therapeutics

Location

Houston, Texas, United States

About

Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. Early clinical studies have shown that the company’s lead asset, TTI-101, is well-tolerated and has clinical activity across a broad range of tumors. To learn more, visit www.tvardi.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech